Compound · clinical trials

Iza-bren clinical trials

Also listed in trial records as BMS-986507, BL-B01D1, Izalontamab Brengitecan, BL-BO1D1, Iza-bren / BL-B01D1

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 58 trials in our China, USA, France, Spain, Italy, Japan, UK, Germany, Canada, Australia, Netherlands, Sweden, Switzerland, Brazil, Taiwan, India, Poland, South Korea, Belgium, Austria, Norway, Israel, Mexico, Turkey, Ireland, Czechia, Singapore and Portugal registers that name Iza-bren as an intervention. Synced 10 Nov 2026

58Current trials

39Recruiting now

5Lead sponsors

28Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 10 Nov 2026 · Editorial standards

At a glance

Iza-bren is named as an intervention in 58 current clinical trials in our China, USA, France, Spain, Italy, Japan, UK, Germany, Canada, Australia, Netherlands, Sweden, Switzerland, Brazil, Taiwan, India, Poland, South Korea, Belgium, Austria, Norway, Israel, Mexico, Turkey, Ireland, Czechia, Singapore and Portugal registers. 39 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Sichuan Baili Pharmaceutical Co., Ltd (49). The most-studied condition is Non-small Cell Lung Cancer. The EU clinical trials register (CTIS) separately lists 2 authorised or ongoing trials.

Patient leaflets for Iza-bren

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

Recruiting3967%
Not yet open712%
Active, closed1221%

Trials by phase

Phase 22645%
Phase 31729%
Phase 2/3814%
Phase 159%
Phase 1/223%

Clinical trials of Iza-bren

58 trials

Study	Phase	Status	Lead sponsor	Registers
A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04) NCT06838273 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) NCT06994195 · ClinicalTrials.gov ↗ · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer	Phase 3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07) NCT07502300 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer	Phase 3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01) NCT07582315 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08) NCT07640789 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Stage III	Phase 3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) NCT07648914 · Breast Cancer	Phase 3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02) NCT07680790 · Non-Small Cell Lung Cancer	Phase 3	Recruiting	Bristol-Myers Squibb	USA, India, China, Germany, France, Spain, Italy, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04) NCT07729956 · ClinicalTrials.gov ↗ · Triple-Negative Breast Cancer (TNBC)	Phase 3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) NCT06926868 · Breast Neoplasms	Phase 2/3	Recruiting	Bristol-Myers Squibb	UK, USA, India, China, Germany, France, Spain, Italy, Sweden, Poland, Switzerland, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Australia, Israel
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) NCT07100080 · Non-Small Cell Lung Cancer	Phase 2/3	Recruiting	Bristol-Myers Squibb	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Norway, Canada, Mexico, Japan, South Korea, Taiwan, Singapore
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy NCT07106762 · Urothelial Cancer	Phase 2/3	Recruiting	Bristol-Myers Squibb	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Switzerland, Austria, Czechia, Norway, Canada, Brazil, Japan, Australia, Israel
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02) NCT07554456 · Esophageal Squamous Cell Carcinoma	Phase 2/3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09) NCT07642024 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2/3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors NCT05785039 · ClinicalTrials.gov ↗ · Urinary System Tumor, Solid Tumor	Phase 2	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer NCT05924841 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Phase 2	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors NCT05956587 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma	Phase 2	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors NCT05965856 · ClinicalTrials.gov ↗ · Urothelial Carcinoma, Solid Tumor	Phase 2	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies NCT05990803 · ClinicalTrials.gov ↗ · Cervical Cancer	Phase 2	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors NCT06006169 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 2	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors NCT06008054 · ClinicalTrials.gov ↗ · Esophageal Cancer, Gastric Cancer, Colorectal Cancer	Phase 2	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer NCT06042894 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma NCT06405425 · ClinicalTrials.gov ↗ · Urothelial Carcinoma	Phase 2	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer NCT06437509 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer	Phase 2	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors NCT06437522 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 2	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer NCT06471205 · ClinicalTrials.gov ↗ · Triple-negative Breast Cancer	Phase 2	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors NCT06475300 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, Solid Tumor	Phase 2	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of BL-B01D1 in Patients With Recurrent Glioblastoma NCT06598787 · ClinicalTrials.gov ↗ · Recurrent Glioblastoma	Phase 2	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9) NCT06855771 · Carcinoma, Non-Small-Cell Lung	Phase 2	Recruiting	Bristol-Myers Squibb	UK, USA, China, Germany, France, Spain, Italy, Sweden, Poland, Japan, Australia
A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC NCT06951464 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Recruiting	Sichuan University	China
A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer NCT06962787 · ClinicalTrials.gov ↗ · Renal Cancer	Phase 2	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer NCT06978114 · ClinicalTrials.gov ↗ · Advanced Biliary Tract Cancer	Phase 2	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma NCT06986785 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma	Phase 2	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer NCT07054567 · ClinicalTrials.gov ↗ · Cervical Cancer, Endometrial Cancer	Phase 2	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies NCT05803018 · ClinicalTrials.gov ↗ · Gynecological Malignant Tumor, Solid Tumor	Phase 1/2	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors NCT06618287 · Lung Cancer, Breast Cancer	Phase 1/2	Recruiting	Bristol-Myers Squibb	UK, USA, France, Spain, Italy, Netherlands, Canada, Taiwan, Australia
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor NCT05194982 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Solid Tumor	Phase 1	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor NCT05262491 · ClinicalTrials.gov ↗ · Gastrointestinal Tumor	Phase 1	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors NCT05470348 · Breast Cancer, Solid Tumor	Phase 1	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors NCT05983432 · Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer	Phase 1	Recruiting	SystImmune Inc	USA, France, Spain, Italy, Japan
A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02) NCT07783321 · Nasopharyngeal Carcinoma (NPC)	Phase 3	Not yet open	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer NCT07641855 · ClinicalTrials.gov ↗ · Castration-resistant Prostate Cancer	Phase 2/3	Not yet open	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) NCT07739186 · ClinicalTrials.gov ↗ · Non-squamous Non-small Cell Lung Cancer	Phase 2/3	Not yet open	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05) NCT07739199 · ClinicalTrials.gov ↗ · Squamous Non-small-cell Lung Cancer	Phase 2/3	Not yet open	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma NCT07797881 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma (NPC)	Phase 2	Not yet open	Sichuan Baili Pharmaceutical Co., Ltd	China
Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer NCT07825753 · ClinicalTrials.gov ↗ · Advanced or Metastatic Pancreatic Adenocarcinoma, Advanced or Metastatic Breast Cancer (BC)	Phase 2	Not yet open	Fudan University	China
A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT07827261 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Not yet open	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01) NCT06118333 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Active, closed	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01) NCT06304974 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 3	Active, closed	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01) NCT06343948 · ClinicalTrials.gov ↗ · HR+HER2- Breast Cancer	Phase 3	Active, closed	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01) NCT06382116 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 3	Active, closed	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02) NCT06382129 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 3	Active, closed	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02) NCT06382142 · ClinicalTrials.gov ↗ · Triple-Negative Breast Cancer	Phase 3	Active, closed	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03) NCT06500026 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Phase 3	Active, closed	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01) NCT06857175 · ClinicalTrials.gov ↗ · Urothelial Carcinoma	Phase 3	Active, closed	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer NCT05880706 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Active, closed	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer NCT06498986 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Active, closed	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma NCT06787664 · ClinicalTrials.gov ↗ · Chordoma	Phase 2	Active, closed	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors NCT05393427 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Urinary Tumors, Other Solid Tumors	Phase 1	Active, closed	Sichuan Baili Pharmaceutical Co., Ltd	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Iza-bren in the EU trials register (CTIS)

2 trials

Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Iza-bren. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.

Study	Phase	Status	Sponsor	Countries
A Phase III, Randomized, Open label Study of Izalontamab Brengitecan (Iza-bren/BMS-986507/BL-B01D1) in Combination with Osimertinib versus Osimertinib Monotherapy or Osimertinib in combination with Platinum-based Chemotherapy as First-Line Therapy in Patients with EGFR-Mutant Locally Advanced or Metastatic Non-small Cell Lung Cancer 2026-526486-21-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	Bristol-Myers Squibb Services Unlimited Company	Germany, Italy, France
IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy 2025-521908-22-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	Bristol-Myers Squibb Services Unlimited Company	Poland, Germany, Italy + 7 more

Conditions studied with Iza-bren

47 conditions

Non-small Cell Lung Cancer9 Solid Tumor5 Breast Cancer4 Non-Small Cell Lung Cancer3 Urothelial Carcinoma3 Small Cell Lung Cancer3 Nasopharyngeal Carcinoma3 Cervical Cancer2 Extensive-stage Small-cell Lung Cancer2 Head and Neck Squamous Cell Carcinoma2 Nasopharyngeal Carcinoma (NPC)2 Esophageal Squamous Cell Carcinoma2

All 47 conditions

Condition (as registered)	Trials
Non-small Cell Lung Cancer	9
Solid Tumor	5
Breast Cancer	4
Non-Small Cell Lung Cancer	3
Urothelial Carcinoma	3
Small Cell Lung Cancer	3
Nasopharyngeal Carcinoma	3
Cervical Cancer	2
Extensive-stage Small-cell Lung Cancer	2
Head and Neck Squamous Cell Carcinoma	2
Nasopharyngeal Carcinoma (NPC)	2
Esophageal Squamous Cell Carcinoma	2
Esophageal Cancer	2
Urothelial Cancer	1
Lung Cancer	1
Breast Neoplasms	1
Carcinoma, Non-Small-Cell Lung	1
Advanced Biliary Tract Cancer	1
Triple-Negative Breast Cancer	1
Gastrointestinal Tumor	1
Locally Advanced or Metastatic Solid Tumor	1
Recurrent Glioblastoma	1
Squamous Non-small-cell Lung Cancer	1
Locally Advanced or Metastatic Urinary Tumors	1
Other Solid Tumors	1
Non-small Cell Lung Cancer Stage III	1
HR+HER2- Breast Cancer	1
Biliary Tract Cancer	1
Triple-Negative Breast Cancer (TNBC)	1
Triple-negative Breast Cancer	1
Non-squamous Non-small Cell Lung Cancer	1
Endometrial Cancer	1
Epithelial Ovarian Cancer	1
Fallopian Tube Cancer	1
Primary Peritoneal Cancer	1
Advanced Hepatocellular Carcinoma	1
Gastric Cancer	1
Colorectal Cancer	1
Gynecological Malignant Tumor	1
Castration-resistant Prostate Cancer	1
Chordoma	1
Renal Cancer	1
Urinary System Tumor	1
Non Small Cell Lung Cancer	1
Nasopharyngeal Cancer	1
Advanced or Metastatic Pancreatic Adenocarcinoma	1
Advanced or Metastatic Breast Cancer (BC)	1

By country register

Register	Trials	Recruiting
Clinical trials in China	56	37
Clinical trials in USA	7	7
Clinical trials in France	7	7
Clinical trials in Spain	7	7
Clinical trials in Italy	7	7
Clinical trials in Japan	6	6
Clinical trials in UK	5	5
Clinical trials in Germany	5	5
Clinical trials in Canada	5	5
Clinical trials in Australia	5	5
Clinical trials in Netherlands	3	3
Clinical trials in Sweden	3	3
Clinical trials in Switzerland	3	3
Clinical trials in Brazil	3	3
Clinical trials in Taiwan	3	3
Clinical trials in India	3	3
Clinical trials in Poland	3	3
Clinical trials in South Korea	3	3
Clinical trials in Belgium	2	2
Clinical trials in Austria	2	2
Clinical trials in Norway	2	2
Clinical trials in Israel	2	2
Clinical trials in Mexico	2	2
Clinical trials in Turkey	2	2
Clinical trials in Ireland	1	1
Clinical trials in Czechia	1	1
Clinical trials in Singapore	1	1
Clinical trials in Portugal	1	1
EU register (CTIS)	2	—

A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.

Related compounds

Questions about Iza-bren trials

How many clinical trials are testing Iza-bren?

58 current trials in our China, USA, France, Spain, Italy, Japan, UK, Germany, Canada, Australia, Netherlands, Sweden, Switzerland, Brazil, Taiwan, India, Poland, South Korea, Belgium, Austria, Norway, Israel, Mexico, Turkey, Ireland, Czechia, Singapore and Portugal registers name Iza-bren (also registered as BMS-986507) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.

Are Iza-bren trials recruiting patients?

Yes. 39 of the 58 trials are recruiting: 37 with sites in China, 7 with sites in USA, 7 with sites in France, 7 with sites in Spain, 7 with sites in Italy, 6 with sites in Japan, 5 with sites in UK, 5 with sites in Germany, 5 with sites in Canada, 5 with sites in Australia, 3 with sites in Netherlands, 3 with sites in Sweden, 3 with sites in Switzerland, 3 with sites in Brazil, 3 with sites in Taiwan, 3 with sites in India, 3 with sites in Poland, 3 with sites in South Korea, 2 with sites in Belgium, 2 with sites in Austria, 2 with sites in Norway, 2 with sites in Israel, 2 with sites in Mexico, 2 with sites in Turkey, 1 with sites in Ireland, 1 with sites in Czechia, 1 with sites in Singapore and 1 with sites in Portugal. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Iza-bren clinical trials?

Sichuan Baili Pharmaceutical Co., Ltd (49), Bristol-Myers Squibb (6), SystImmune Inc (1) and Sichuan University (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there Iza-bren clinical trials in Ireland?

Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Iza-bren works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Iza-bren works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Iza-bren (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.